Application of damage responsive polymer nanoparticle loaded polypeptide in treatment of cardiovascular diseases

Through damage-responsive polymer nanoparticle loading technology, the peroxide-sensitive nanocomposite PEG-PPS-PEG achieves targeted release of GHRH agonists at the site of myocardial infarction, solving the instability and difficulty in targeting of polypeptide drugs Heart-oriented problems significantly improve the therapeutic effect and drug stability of myocardial infarction.

CN119060320APending Publication Date: 2024-12-03HANGZHOU NOVELPEPTIDE BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411191586.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing polypeptide drugs such as GHRH agonists have problems with instability and short half-life in the treatment of myocardial infarction, and are difficult to effectively target the heart, resulting in poor treatment effect and accompanied by side effects.

Method used

The damage-responsive polymer nanoparticle loading polypeptide technology is used to load the GHRH agonist NFT401 through the peroxide-sensitive nanocomposite PEG-PPS-PEG, and targeted release is achieved at the site of myocardial infarction by peroxide-triggered means, improving the Drug stability and therapeutic efficiency.

Benefits of technology

It significantly reduces apoptosis and fibrosis of cardiomyocytes, improves cardiac function recovery, reduces the distribution of drugs in non-targeted tissues, reduces side effects, and reduces the number of injections without increasing the total amount of drugs, Achieve the same therapeutic effect as nude peptide.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060320A_ABST
    Figure CN119060320A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, in particular to application of damage-responsive polymer nanoparticle loaded polypeptide to treatment of cardiovascular diseases. The preparation method comprises the following steps: sequentially adding sodium hydroxide and a toluenesulfonyl chloride solution into a polyethylene glycol methyl ether solution to react, and extracting to remove a solvent to obtain PEG-toluenesulfonyl; sequentially adding a potassium thioacetate solution and trimethylamine into the PEG-tosyl solution, and then incubating to obtain polyethylene glycol thioacetate; and sequentially adding sodium methoxide, propylene sulfide and iodoacetamide into the polyethylene glycol thioacetate solution, reacting, and precipitating to obtain the product. The invention provides an innovative method for delivering peptide drugs for myocardial infarction by using nano-particles sensitive to peroxide generated by injury. The NPs not only can deliver the peptide medicine to the infarcted heart, but also can directly reduce the peroxide level of the injured part, and has a more effective treatment effect on the infarcted heart compared with a naked peptide.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to the use of damage-responsive polymer nanoparticles loaded with polypeptides in the treatment of cardiovascular diseases. Background Art

[0002] Myocardial infarction (MI) has become a major threat to human health and life due to its high morbidity and mortality. Peptide drugs such as growth hormone-releasing hormone (GHRH) agonists have been shown to have the ability to resist serum deprivation and isoproterenol-induced apoptosis in adult rat ventricular myocytes (ARVMs) and H9C2 rat cardiomyocytes (CMs). Consistent with the results of in vitro studies, a series of studies conducted by Kanashiro-Takeuchi et al. demonstrated that GHRH agonists can protect myocardial injury caused by acute infarction in rats in vivo. Pretreatment with GHRH reduced myocardial infarction area and cardiac systolic dysfunction by activating the reperfusion injury repair kinase (RISK) and survival activating factor enhanced (SAFE) pathways. GHRH agonists may be a new potential therapeutic drug that prevents apoptosis of CMs and reduces the degree of fibrosis after MI by activating GHRH receptors. GHRH agonists as peptide drugs have multiple advantages over protein or antibody drugs: they are easy to synthesize, have high specificity and low toxicity. However, GHRH agonists have some obvious disadvantages: instability and short half-life. In addition, GHRH receptors are expressed in many tissues and organs, which may cause side effects in other organs. Therefore, it is necessary to study strategies to overcome the instability of peptide drugs and enhance their release at the site of injury.

[0003] The application of nanotechnology in medicine is at the forefront of modern healthcare and represents an effective treatment modality. In recent years, the U.S. Food and Drug Administration has approved a series of first-generation nanoproducts for clinical use, and liposomes and polymer drug conjugate nanosystems are also under clinical and preclinical development. The design of drug delivery systems (DDS) has attracted increasing attention because DDS can effectively deliver a variety of therapeutic drugs to the disease site. Peroxides such as Reactive Oxidative Species (ROS) are one of the most common biostimuli. Damage-responsive DDS show great potential in a range of biomedical applications, such as targeted therapy for cancer or inflammation-related diseases. In ischemic myocardium, myocardial damage produces a large amount of peroxides. In addition, it has been shown that damage-responsive fluorescent nanoparticles are highly specific and targeted to ischemic / perfused myocardium within the first 24 hours after myocardial ischemia-reperfusion.

[0004] Therefore, how to provide a damage-responsive drug delivery system to improve the stability of polypeptide drugs and apply them to the treatment of myocardial infarction is a technical problem that technicians in this field urgently need to solve. Summary of the invention

[0005] The purpose of the present invention is to provide application of damage-responsive polymer nanoparticles loaded with polypeptides in treating cardiovascular diseases.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides a method for preparing a damage-responsive nanopolymer, comprising the following steps:

[0008] (1) adding sodium hydroxide and toluenesulfonyl chloride solution to polyethylene glycol methyl ether solution in sequence for reaction, extracting the reaction solution, removing the solvent, and obtaining PEG-toluenesulfonyl;

[0009] (2) dissolving PEG-toluenesulfonyl with a solvent to obtain a PEG-toluenesulfonyl solution; sequentially adding a potassium thioacetate solution and trimethylamine, incubating, filtering the precipitate and removing the solvent, extracting the remaining product, and removing the solvent to obtain polyethylene glycol thioacetate;

[0010] (3) dissolving polyethylene glycol thioacetate with a solvent and degassing to obtain a polyethylene glycol thioacetate solution; sequentially adding sodium methoxide, propylene sulfide and iodoacetamide, reacting and precipitating to obtain a damage-responsive nano-copolymer PEG-PPS-PEG.

[0011] Preferably, in step (1), the ratio of sodium hydroxide, toluenesulfonyl chloride solution and polyethylene glycol methyl ether solution is 3-5 g:13-17 mL:15-25 mL; the concentration of the toluenesulfonyl chloride solution is 30-36 g / 100 mL; the concentration of the polyethylene glycol methyl ether solution is 7-8 g / 100 mL; the reaction time is 10-14 h; and the extraction is performed by extracting with dichloromethane and water three times.

[0012] Preferably, the concentration of the PEG-toluenesulfonyl solution in step (2) is 4-5 g / 100 mL; the concentration of the potassium thioacetate solution is 11-12 g / 100 mL; the ratio of the PEG-toluenesulfonyl solution, potassium thioacetate solution, and trimethylamine is 18-22 mL: 18-22 mL: 400-600 μL; and the extraction is performed by alternating extraction with dichloromethane and water for 3 times.

[0013] Preferably, the concentration of the polyethylene glycol thioacetate solution in step (3) is 3-5 g / 100 mL; the ratio of the polyethylene glycol thioacetate solution, sodium methoxide, propylene sulfide and iodoacetamide is 4-6 mL: 14-18 mg: 900-940 mg: 100-180 mg.

[0014] Preferably, in step (3), after adding sodium methoxide, the reaction time is 25 to 35 minutes, and then propylene sulfide is added; after adding propylene sulfide, the reaction time is 40 to 50 minutes, and then iodoacetamide is added; and the reaction time is 10 to 14 hours.

[0015] The present invention also provides a nano copolymer PEG-PPS-PEG with damage response and sensitive to peroxide products produced by damage, which is obtained by the preparation method. It can load the hydrophilic polypeptide GHRH agonist (NFT401) into the inner core of the vesicle (PPS-PEG@NFT401). The hydrophobic interaction of the propylene sulfide skeleton enhances the stability of the drug in the peripheral circulation in vivo, and ROS can trigger drug release by in situ oxidation of PPS from hydrophobic thioether to sulfoxide, and finally the hydrophilic sulfoxide can effectively release the encapsulated drug polypeptide.

[0016] The present invention also provides a drug delivery system, comprising the damage-responsive nano copolymer and a hydrophilic polypeptide drug.

[0017] Preferably, the hydrophilic polypeptide drug is the GHRH agonist NFT401; the amino acid sequence of the GHRH agonist NFT401 is:

[0018] PhAcTyr-dAla-Asp-Ala-Ile-Phe-Thr-Thr-Ser-Tyr-Arg-Orn-Val-Leu-Abu-Gln-Leu-Ser-Ala-Arg-Orn-Leu-Leu-Gln-Asp-Ile-Nle-Asp-Agm.

[0019] Explanation: The above sequence is PhAc (modified) tyrosine-D-alanine-aspartic acid-alanine-isoleucine-phenylalanine-threonine-threonine-serine-tyrosine-arginine (YANAIFTTSYR (as shown in SEQ ID NO: 1))-ornithine-valine (V)-leucine (L)-(2-aminobutyric acid)-glutamine (Q)-leucine (L)-serine (S)-alanine (A)-arginine (R) (as shown in SEQ ID NO: 2)-ornithine-leucine (L)-leucine (L)-glutamine (Q)-aspartic acid (N)-isoleucine (I) (as shown in SEQ ID NO: 3)-norleucine-aspartic acid (N)-agmatine. The target peptide is chemically synthesized with a purity of >97%.

[0020] The present invention also provides a pharmaceutical composition, comprising the drug delivery system.

[0021] The present invention also provides the use of the pharmaceutical composition in preparing a drug for treating myocardial infarction.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] In this study, we proposed an innovative method for cardiac delivery of peptide drugs using a peroxide ROS-sensitive nanoparticle (NP) system. NPs not only deliver peptide drugs to the heart, but also directly reduce peroxide levels at the site of injury, which has a more effective therapeutic effect on the infarcted heart compared with the use of naked peptides. NPs release peptide drugs in a peroxide-responsive manner and target the infarcted heart, significantly reducing CM apoptosis and cardiac fibrosis.

[0024] Effective peptide drug delivery to the heart has always been a challenge. Typically, peptide drugs are delivered via subcutaneous injection, which is inconvenient. Although hormone peptide drugs have the advantages of high sensitivity and specificity, they are difficult to deliver effectively and require high doses, leading to side effects. By applying a damage-responsive nanocoating on the peptide, we not only protect the peptide but also target it to the injured heart for more effective, faster, and more efficient treatment. The main advantages of this drug delivery system are: passive targeting of the peroxide response increases the drug concentration at the lesion site while reducing its distribution in non-targeted tissues and organs, thereby reducing adverse drug reactions; compared with naked peptide administration, the number of drug injections required is reduced to achieve similar therapeutic effects.

[0025] Nano drug delivery systems have strong vascular penetration ability, especially for newly formed vascular systems and ischemic damaged blood vessels. Due to the rich blood vessels, large vascular space and lack of lymphatic drainage in tumor tissues, nano drug delivery systems can form a drug-rich microenvironment around tumor tissues. Therefore, nano drug delivery systems are widely used in solid tumors. After myocardial infarction injury, common vascular endothelial damage and new capillaries around the ischemic area create a permeable local microenvironment for nano drug delivery. Our results showed that PEG-PPS-PEG@NFT401 NPs accumulated on the infarcted heart ( Figure 5 ). In addition to targeted delivery, PEG-PPS-PEG@NFT401 NPs may also consume some peroxides, thereby reducing ischemic damage in CMs. Our data showed that PEG-PPS-PEG can reduce CM cell apoptosis caused by injury-induced peroxide production ( Figure 3 ). Combining these benefits, we demonstrated that PEG-PPS-PEG encapsulated peptides outperformed naked peptides in terms of therapeutic efficacy. Without changing the total amount of NFT401 peptide, PEG-PPS-PEG@NFT401 NPs only required one-third of the number of injections to achieve the same therapeutic effect on myocardial infarction as naked NFT401 ( Figure 6 )

[0026] The present study shows that the nano drug delivery system can be recognized and engulfed by mononuclear phagocytic immune cells in the blood, liver, spleen and lymphatic system. After uptake, immune cells migrate to the site of inflammation, realizing a new nano drug delivery mechanism. Our data show that CMs can take up PEG-PPS-PEG@NFT401NPs( Figure 2 ). Further studies are needed to determine whether immune cells deliver PEG-PPS-PEG@NFT401 NPs to the infarcted heart.

[0027] Although PEG-PPS-PEG@NFT401 NPs achieved targeted release and reduced the number of injections, this design has certain limitations: 1) Compared with peptides without PEG-PPS-PEG coating, the targeting efficiency was only improved by 10% 30 minutes after myocardial infarction ( Figure 5 C) There is room for improvement; 2) Nanoparticles of 20-200 nm can stay in the circulation for a longer time, most of them are metabolized by the liver and kidneys, and only a few reach the heart; 3) The safety of nanocarriers and their fate in the body still need to be further studied. Therefore, further research is needed to fully understand the targeted release of peptide drugs in vivo. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0029] Figure 1 :Synthesis and characterization of damage-responsive vesicles encapsulating the GHRH agonist NFT401 polypeptide. (A) Schematic diagram of damage-responsive PEG-PPS-PEG vesicles; (B) Morphological changes of PEG-PPS-PEG vesicles before and after H2O2 (200 μmol) treatment; (C) Diameter of PEG-PPS-PEG vesicles; (D) Cumulative release of NFT401 from PEG-PPS-PEG vesicles in the presence of 200 μmol H2O2.

[0030] Figure 2 : PEG-PPS-PEG@NFT401 NPs are internalized by cardiomyocytes. (A) Fluorescence microscopy images (10× objective) of H9C2 CMs after exposure to different concentrations of FITC-labeled PEG-PPS-PEG@NFT401 NPs for 6 h. Perinuclear aggregation of NPs was detected. Scale bar: 100 μm. (B) Fluorescence microscopy images (20× objective) of H9C2 CMs mixed with 20 μg / ml FITC-labeled PEG-PPS-PEG@NFT401 NPs for 9 h. FITC / NP (green) colocalizes with F-Actin (red). Scale bar: 50 μm.

[0031] Figure 3 : Effects of PEG-PPS-PEG@NFT401 NPs on peroxide production and apoptosis in CMs. Cells were cultured for 24 h under normal conditions, hypoxia, and serum-free conditions with or without the addition of PEG-PPS-PEG@NFT401 NPs, or empty PEG-PPS-PEG, or naked NFT401. (A) Peroxide production in CMs was analyzed by DCFH-A fluorescence staining and quantified by flow cytometry; (B) Representative images are flow cytometry detection of H9C2 cells after Annexin V (FITC) and PI staining. (C) Quantitative detection of the positive ratio of Annexin IV and PI positive cells, representing the level of cell apoptosis. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, ns: no statistical difference.

[0032] Figure 4: Cy5-labeled PEG-PPS-PEG@NFT401 nanoparticles were injected subcutaneously 10 minutes after myocardial infarction. (A) The accumulation of nanoparticles in the lung, heart, liver and kidney was observed at 5h, 24h, 48h and 72h; (B) The fluorescence intensity of the heart was quantified and expressed as the ratio of heart to liver.

[0033] Figure 5 : Targeted delivery of NFT401 peptide to the infarcted heart via PEG-PPS-PEG vesicles. NFT401-Cy5 or PEG-PPS-PEG@NFT401-Cy5 NPs were intravenously injected into mice 10 min after myocardial infarction, and fluorescence images of the heart and lungs were collected 30 min later. (A) Fluorescence images of the heart and lungs; (B) Quantification of the fluorescence intensity ratio of the heart to the lungs; **p<0.01, n=3. (C) Fluorescence images of four equal parts of the heart cut vertically from the base to the apex; the blue arrows point to the ligation sites. More red fluorescence was observed at the ligation sites.

[0034] Figure 6 PEG-PPS-PEG@NFT401 NPs improve cardiac function in infarcted hearts. (A) Schematic diagram of the experimental timeline in mice. After myocardial infarction, PBS (NC) or naked NFT401 peptide or empty PEG-PPS-PEG was injected via the tail vein; PEG-PPS-PEG@NFT401 NPs (NPs) were injected once every 3 days. (B) Ejection fraction (EF) and fractional shortening (FS) of mouse hearts were detected by ultrasound at 0, 7, and 28 days after injection; (C) Masson & trichrome staining, 28 days after myocardial infarction recovery. (D) Quantification of scar size; **P<0.01, n=5-6.

[0035] Figure 7 : A diagram showing the working principle of the damage-responsive nanopolymer of the present invention. DETAILED DESCRIPTION

[0036] The present invention provides a method for preparing a damage-responsive nanopolymer, comprising the following steps:

[0037] (1) adding sodium hydroxide and toluenesulfonyl chloride solution to polyethylene glycol methyl ether solution in sequence for reaction, extracting the reaction solution, removing the solvent, and obtaining PEG-toluenesulfonyl;

[0038] (2) dissolving PEG-toluenesulfonyl with a solvent to obtain a PEG-toluenesulfonyl solution; sequentially adding a potassium thioacetate solution and trimethylamine, incubating, filtering the precipitate and removing the solvent, extracting the remaining product, and removing the solvent to obtain polyethylene glycol thioacetate;

[0039] (3) dissolving polyethylene glycol thioacetate with a solvent and degassing to obtain a polyethylene glycol thioacetate solution; sequentially adding sodium methoxide, propylene sulfide and iodoacetamide, reacting and precipitating to obtain a damage-responsive nano-copolymer PEG-PPS-PEG.

[0040] In the present invention, the ratio of the sodium hydroxide, toluenesulfonyl chloride solution and polyethylene glycol methyl ether solution in step (1) is 3-5 g: 13-17 mL: 15-25 mL; preferably 4 g: 14-16 mL: 17-23 mL; further preferably 4 g: 15 mL: 19-21 mL; more preferably 4 g: 15 mL: 20 mL.

[0041] In the present invention, the concentration of the toluenesulfonyl chloride solution in step (1) is 30-36 g / 100 mL; preferably 31-35 g / 100 mL; more preferably 32-34 g / 100 mL; and more preferably 33 g / 100 mL.

[0042] In the present invention, the concentration of the polyethylene glycol methyl ether solution in step (1) is 7-8 g / 100 mL, preferably 7.5 g / 100 mL.

[0043] In the present invention, the reaction time of step (1) is 10 to 14 hours, preferably 11 to 13 hours, and more preferably 12 hours.

[0044] In the present invention, the extraction in step (1) is performed by extracting with dichloromethane and water three times.

[0045] In the present invention, the concentration of the PEG-toluenesulfonyl solution in step (2) is 4-5 g / 100 mL, preferably 4.5 g / 100 mL.

[0046] In the present invention, the concentration of the potassium thioacetate solution in step (2) is 11-12 g / 100 mL, preferably 11.5 g / 100 mL.

[0047] In the present invention, the ratio of the PEG-toluenesulfonyl solution, potassium thioacetate solution and trimethylamine in step (2) is 18-22 mL: 18-22 mL: 400-600 μL; preferably 19-21 mL: 19-21 mL: 440-560 μL; further preferably 20 mL: 20 mL: 480-520 μL; more preferably 20 mL: 20 mL: 500 μL.

[0048] In the present invention, the extraction in step (2) is performed by alternately extracting with dichloromethane and water for 3 times.

[0049] In the present invention, the concentration of the polyethylene glycol thioacetate solution in step (3) is 3 to 5 g / 100 mL, preferably 4 g / 100 mL.

[0050] In the present invention, the ratio of the polyethylene glycol thioacetate solution, sodium methoxide, propylene sulfide and iodoacetamide in step (3) is 4-6 mL: 14-18 mg: 900-940 mg: 100-180 mg; preferably 5 mL: 15-17 mg: 910-930 mg: 110-170 mg; further preferably 5 mL: 16 mg: 920 mg: 120-160 mg; more preferably 5 mL: 16 mg: 920 mg: 140 mg.

[0051] In the present invention, step (3) needs to react for 25 to 35 minutes after adding sodium methoxide, and then add propylene sulfide; preferably 27 to 33 minutes; more preferably 27 to 31 minutes; more preferably 30 minutes.

[0052] In the present invention, step (3) requires a reaction time of 40 to 50 minutes after the addition of propylene sulfide, and then the addition of iodoacetamide; preferably 42 to 48 minutes; more preferably 44 to 46 minutes; and more preferably 45 minutes.

[0053] In the present invention, the reaction time of step (3) is 10 to 14 hours, preferably 11 to 13 hours, and more preferably 12 hours.

[0054] The invention also provides a nano copolymer with damage response obtained by the preparation method.

[0055] The present invention also provides a drug delivery system, comprising the damage-responsive nano copolymer and a hydrophilic polypeptide drug.

[0056] In the present invention, the hydrophilic polypeptide drug is NFT401.

[0057] The present invention also provides a pharmaceutical composition, comprising the drug delivery system.

[0058] The present invention also provides the use of the pharmaceutical composition in preparing a drug for treating myocardial infarction.

[0059] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0060] Experimental Example 1

[0061] Preparation of poly(ethylene glycol) poly(propylene sulfide) poly(ethylene glycol) polymers:

[0062] 1. Synthesis of PEG-toluenesulfonyl:

[0063] 1.5 g of polyethylene glycol methyl ether (Sigma-Aldrich, Mw = 1 kDa) was dissolved in 20 mL of 1:1 (v / v) tetrahydrofuran (THF) / water mixture, and then 4.0 g of sodium hydroxide was added in an ice bath under vigorous stirring. Subsequently, 5.0 g of p-toluenesulfonyl chloride was dissolved in 15 mL of tetrahydrofuran and then added dropwise to the above solution. After reacting overnight (12 h) under the above conditions, the solution was extracted three times with dichloromethane and distilled water. The solvent was removed to obtain a transparent viscous liquid PEG-toluenesulfonyl.

[0064] 2. Synthesis of polyethylene glycol thioacetate

[0065] Dissolve 0.9 g of PEG-tosyl sample in 20 mL of dichloromethane. Dissolve 2.28 g of potassium thioacetate in 20 ml of a 1:1 dichloromethane / methanol (MeOH) mixture and add the above solution. After adding 500 uL of trimethylamine, incubate the mixture for 12 hours. Filter the precipitate and remove the solvent using a rotary evaporator. The remaining product is extracted three times with dichloromethane and distilled water. Remove the solvent to obtain a transparent viscous liquid polyethylene glycol thioacetate.

[0066] 3. Synthesis of PEG-PPS-PEG three-stage polymer

[0067] 200mg PEG thioacetate sample is dissolved among the 5mL THF, and with nitrogen, solution is degassed 3 times.In the solution after the 16mg sodium methylate sample injection degassed among the 0.5mL MeOH, and mixture is placed 30 minutes at room temperature.Subsequently, 925mg propylene sulfide is injected into the mixture.After 45 minutes, add 138mg iodoacetamide, and new solution is placed and spend the night (12h).Obtain the final product PEG-PPS-PEG with the ether precipitation of three times of volume.

[0068] Experimental Example 2

[0069] 1. Preparation and characterization of NFT401-loaded vesicles

[0070] NFT401 was loaded into PEG-PPS-PEG-based vesicles by a solvent exchange method. The amphiphilic PEG-PPS-PEG (5 mg, prepared in Experimental Example 1) block copolymer was dissolved in 1 mL of THF and then slowly added dropwise to 2 mL of 0.1 μg / μL NFT401 aqueous solution. The organic solvent was removed using a wheel steam, and the vesicles loaded with NFT401 (PEG-PPS-PEG@NFT401NPs) were purified by three centrifugations at 4000 × g (10 minutes each) using an Amicon Ultra-15 centrifugal filter device (Merck-Centrifugal Pore Company, USA).

[0071] The morphology of the vesicles was examined by transmission electron microscopy (TEM) (HT7700, Hitachi, Japan), and the hydrodynamic diameter of the vesicles was measured by dynamic light scattering (DLS, Zetasizer 3000, Malvern, Southland, MA).

[0072] NFT401 was first fluorescently labeled (lysine with fluorescein isothiocyanate (FITC) or near-infrared fluorescent probe Cy5 (Sangon, Shanghai, China)) for quantification of NFT401 loading and release.

[0073] After PEG-PPS-PEG@NFT401 NPs were co-cultured with H2O2 for different time periods, PPS was oxidized to convert hydrophobic thioether into sulfoxide and finally into hydrophilic sulfone, the particles were decomposed and the peptide was released. The samples were collected, the supernatant was taken, the fluorescence intensity was measured, and the release amount of GHRH agonist NFT401 was calculated. The vesicle / NFT401 aqueous suspension was stored at -20°C until use.

[0074] Preparation of active reactive nanoparticles encapsulating peptides

[0075] Schematic diagram of PEG-PPS-PEG polymer Figure 1 As shown in A, the polymer self-assembles into a vesicle structure with a diameter of 50 to 180 nm ( Figure 1 B). In the presence of GHRH agonist NFT401, the hydrophilic peptide was introduced into the inner space of the vesicles during the self-assembly process, named PEG-PPS-PEG@NFT401 NPs.

[0076] After 48 h of H2O2 treatment, PPS was oxidized to convert hydrophobic thioether into sulfoxide and finally into hydrophilic sulfone, and the particles were completely decomposed and the peptide was released. The average diameter of the spherical vesicles was about 150 ± 30 nm, which was independent of the polymer concentration ( Figure 1 C). It can effectively induce the release of H2O2 from NFT401 vesicles, reaching 90% after 72h of incubation, while the release of NFT401 from the control group (where hydrogen peroxide was replaced by water) was only 30% ( Figure 1 D).

[0077] In vitro cellular uptake of PEG-PPS-PS-PEG@NFT401NPs

[0078] The endocytosis of nanoparticles (NPs) is the first step in delivering loaded drug molecules inside cells. The present invention uses FITC-labeled PEG-PPS-PEG@NFT401NPs (FITC / NP). After mixing FITC / NP with CM (cardiac myocytes) for 6 hours, the fluorescence signal around the cell nucleus is detected in a concentration-dependent manner ( Figure 2A), indicating that cells have engulfed NPs. FITC / NP can overlap with the cytoskeletal protein F-Actin ( Figure 2 B), confirming that NPs were indeed phagocytosed by cells.

[0079] 2. Determination of intracellular reactive oxygen species

[0080] H9C2 rat cardiomyocytes were purchased from American Type Culture Collection (ATCC). H9C2 cells or primary neonatal rat cardiomyocytes (NRCM) were cultured at 1×10 5 Cells / mL concentration, 2mL per well were seeded in 6-well plates. Then H9C2 cells and primary neonatal rat cardiomyocytes (NRCM) were divided into four groups, PBS, NFT401 peptide (concentration 3μM), PEG-PPS-PEG (vesicles only, no peptide added), PEG-PPS-PEG@NFT401NPs (vesicle loaded peptide group, concentration 20μg / ml), after 24 hours under hypoxia and serum-free conditions, 500μL dichlorodihydrofluorescein diacetate (DCFH-A) (Beijing Biotechnology Company, Shanghai, China) was added, diluted with serum-free medium, and stained for 30min. After washing three times with serum-free medium, cells were detected by flow cytometry (BD Biosciences, San Jose, CA, USA).

[0081] Annexin V / PI staining to detect cell apoptosis

[0082] Isolation and culture of neonatal rat cardiomyocytes

[0083] The newborn mice used in the experiment were all C57BL / 6L newborn mice within 24 hours after birth. The mice were soaked in 75% alcohol for 30 seconds; a small hole was cut from the midline of the left sternum costal margin of the mouse with high-pressure ophthalmic scissors, and the heart was squeezed; the heart was cut open and then placed in pre-cooled PBS buffer; after rinsing 3 sides with PBS buffer, the heart was cut into 1mm pieces with scissors. 3Tissue fragments; transfer the tissue fragments into a 50ml centrifuge tube containing 10ml 0.05% w / v trypsin / EDTA, digest with 0.05% w / v collagenase, and digest on a 37°C constant temperature shaker for 10 minutes; centrifuge at low speed to obtain a precipitate, carefully aspirate the supernatant, and add it to the neutralization medium (80% high-glucose DMEM and 20% fetal bovine serum) to stop digestion; add 10ml of digestive enzyme to the precipitate obtained by centrifugation, and repeat the digestion 6 times, 10 minutes each time, until the tissue mass is basically digested; all digestion products pass through a 70mm sterile filter to remove undigested tissue fragments. Centrifuge again at 1000rpm for 10 minutes, and the resulting pellet is the cardiomyocytes; resuspend the cell plate and the fibroblasts that first adhere to the wall with an appropriate amount of high-glucose DMEM; after 1.5 hours, aspirate the non-adherent cells, and then centrifuge at 1250 cells / mm 2 The density was plated on a cell plate coated with 0.5% gelatin. Neonatal rat cardiomyocytes were cultured in DMEM containing 10% fetal bovine serum (FBS), 4.5 g / L glucose, and 0.1 mM 5-bromo-2-deoxyuridine (BrdU); cardiomyocytes were cultured for 24-48 hours, during which time they did not move, and subsequent experiments were performed after the cells completely adhered to the wall.

[0084] Neonatal rat cardiomyocytes NRCM were cultured in normal culture (NC) or hypoxic and serum-free conditions without (control) or with PEG-PPS-PEG (concentration 20 μg / ml). After 24 h, the cells were digested, washed with PBS, and harvested and incubated with Allanin V-FITC for 30 min according to the manufacturer's instructions (Kanajima, Tokyo, Japan). After treatment, the cells were analyzed by flow cytometry (BD Biosciences, San Jose, CA, USA).

[0085] In vitro bioactivity of PEG-PPS-PEG@NFT401 NPs

[0086] To determine whether PEG-PPS-PEG@NFT401 NPs can reduce the degenerative effects of peroxides on cells, H9C2 cells and neonatal rat cardiomyocytes (NRCMs) were cultured under normal or hypoxic serum-free conditions to simulate the environment of cardiomyocytes after myocardial infarction (MI). When NFT401 or PEG-PPS-PEG or PEG-PPS-PEG@NFT401 NPs were added to the culture, ROS production by CMs was reduced ( Figure 3 A). PEG-PPS-PEG, NFT401 and NPs significantly reduced cell apoptosis induced by hypoxia and serum-free culture conditions ( Figure 3 B and C).

[0087] 3. In vitro imaging

[0088] Mice were subcutaneously injected with Cy5-labeled PEG-PPS-PEG@NFT401 NPs (15 μg / mouse) or control solution (equal volume of saline) and sacrificed 30 min later. In vitro imaging of different organs was collected. Fluorescence images were acquired using IVIS Lumina III imaging system (Perkin Elmer). The following acquisition parameters were used: excitation filter range: 680-740 nm, emission filter: 790 nm, exposure time: 2 s, binning factor 4, f / Stop: 2. Spectral decomposition, image processing, and analysis were performed using In Vivo Image 4.3.1 software (PerkinElmer).

[0089] In vivo targeting ability of PEG-PPS-PEG@NFT401 NPs to infarcted hearts

[0090] To investigate the targeting ability of PEG-PPS-PEG@NFT401 to the infarcted heart, we labeled the NFT401 peptide with the fluorescent probe Cy5 (PEG-PPS-PEG@NFT401-Cy5). After PEG-PPS-PEG@NFT401-Cy5 was subcutaneously injected into mice, the expression of PEG-PPS-PEG-PEG@NFT401-Cy5 at different time points after injection in mice ( Figure 4 ) The liver and kidney had the highest fluorescence intensity in MI and non-MI (myocardial infarction) mice at all time points. The relative fluorescence intensity of the infarcted heart was significantly higher than that of the normal heart ( Figure 4 B), indicating that PEG-PPS-PEG@NFT401NPs can actively aggregate to the infarcted heart.

[0091] 4. Method for establishing mouse myocardial infarction model

[0092] All animal experiments were approved by the Animal Use and Care Committee of Zhejiang University and in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health. This study was approved by the Ethics Review Committee of the Second Affiliated Hospital of Zhejiang University. Mice (C57BL / 6) were anesthetized with isoflurane. All mice had free access to normal diet and water. The mice were shaved before surgery and the skin was disinfected with 75% ethanol. Male C57BL / 6J mice (8-10 weeks, 22-25g) were divided into 4 groups, 7-9 mice in each group, namely PBS, NFT401 (5μg / mouse / day), PEG-PPS-PEG (no peptide) and PEG-PPS-PEG@NFT401NPs (15μg / mouse / 3 days) groups. Acute myocardial infarction was achieved by ligation of the left coronary artery. Mice were anesthetized by subcutaneous injection of 1% pentobarbital at a dose of 50mg / kg and fixed on a mouse board in a supine position with their limbs. An 18G intravenous indwelling direct-view mouse endotracheal tube was used, and the small animal ventilator was connected to adjust the parameters for assisted ventilation. The chest was opened layer by layer at the third 3 / 4 of the left edge of the mouse's chest. The left anterior descending coronary artery was ligated with a 7-0 round needle nylon suture. The chest was closed layer by layer, the skin surgical incision was sutured, and the mouse was placed on a constant temperature heating pad to recover, and the mouse's respiratory rate and neurological reflexes were closely observed. After the mice recovered spontaneous breathing and woke up, they were returned to the cage.

[0093] PEG-PPS-PEG@NFT401 NPs were injected into the infarcted heart (PPS represents vesicles without drug loading, and PPS@NFT401-cy5 represents vesicles loaded with drug and labeled)

[0094] To further confirm that PEG-PPS-PEG@NFT401 NPs are ROS-responsive and can aggregate to the infarcted heart, we injected NFT401-Cy5 with or without PEG-PPS-PEG material 10 minutes after myocardial infarction. The fluorescence signal of the mouse hearts injected with PEG-PPS-PEG@NFT401 was significantly higher than that of the mice injected with bare NFT401-Cy5 (10%) ( Figure 5 A and B), in addition, a stronger fluorescence signal can be detected at the location of cardiac ligation ( Figure 5 C). These results indicate that PEG-PPS-PEG@NFT401 can effectively deliver NFT401 peptide to the injury site.

[0095] 5. Mouse cardiac ultrasound examination method

[0096] One day before myocardial infarction in mice, 7 days after myocardial infarction, and 28 days after myocardial infarction, transthoracic echocardiography was performed using the Vevo2000 small animal ultrasound system to evaluate the cardiac function of mice. After depilation of the mouse chest, the mouse was fixed on a 37°C constant temperature plate with tape, and the respiratory curve and electrocardiogram of the mouse were recorded. A standard left ventricular long axis view was acquired at the left ventricular outflow tract position, and then a short axis view perpendicular to the long axis was found, and an M-mode echocardiogram was acquired at the middle of the papillary muscle. At least 5 consecutive cardiac cycles were measured using M-mode echocardiography, and the left ventricular ejection fraction (LVEF) and left ventricular short axis shortening rate (left ventricular shortening fraction, LVFS) were calculated.

[0097] Preparation of mouse heart paraffin sections

[0098] Anesthetize the mouse with an overdose of anesthetic, cut the chest and abdomen layer by layer, expose the heart and liver, and cut at the liver. First, inject 3% potassium chloride from the apex to stop the heart, then inject pre-cooling into the apex, and immediately wash the heart repeatedly with PBS buffer until the liver turns white. Remove the heart, wash it again with PBS buffer, and dry it with absorbent paper. Immediately place the heart in 10% neutral formaldehyde solution, fix it for 24 to 48 hours, dehydrate it with gradient ethanol, and embed it in paraffin. Use a 4μm paraffin slicer to slice, bake it in an incubator at 60℃ for 2 hours, and store it at room temperature.

[0099] Dyeing method

[0100] Masson staining of heart sections was detected by Masson staining kit according to the manufacturer's instructions. Routine separation to water, staining with prepared Weigert's iron hematoxylin staining solution for 10 min, differentiation with acidic ethanol for 15 s, washing with water, blueing with Masson blue solution for 5 min, washing with distilled water for 1 min, and red hematoxylin staining for 10 min. During the above operation, weak acid working solution was prepared in a ratio of distilled water = 2:1, washing with weak acid working solution for 1 min; washing with phosphomolybdic acid solution for 2 min; washing with well-prepared weak acid working solution for 1 min; staining directly in aniline blue staining solution for 2 min; washing with well-prepared weak acid working solution for 1 min; rapid dehydration in 95% ethanol; dehydration with anhydrous ethanol 3 times, 10 seconds each time; sealing with neutral balsam containing xylene.

[0101] Cell immunofluorescence staining method

[0102] Fix the cell slides with 4% paraformaldehyde for 10 minutes, then rinse 3 times with PBS; use 0.1% test film for 10 minutes, rinse 3 times with PBS, and block with 3% BSA for 1 hour at room temperature. Incubate the primary antibody at 4°C overnight according to the recommended concentration of the antibody manual. On the second day, rinse 3 times with PBS, then incubate the corresponding secondary antibody for 2 hours at room temperature, and then rinse 3 times with PBS. Mount the slides with mounting slides containing DAPI.

[0103] Statistical analysis methods

[0104] In the apoptosis experiments, one-way or two-way ANOVA and Student's t-test were used for statistical comparisons of unpaired samples. Prism 7.0 software (GraphPad Software) was used to assess the normality of the data and perform statistical calculations. p < 0.05 was considered significant.

[0105] Peroxide-responsive PEG-PPS-PEG@NFT401 NPs improve cardiac function in myocardial infarction hearts.

[0106] PEG-PPS-PEG NPs or PEG-PPS-PEG@NFT401 NPs (injected once every three days via tail vein); naked NFT401 peptide was injected once a day via tail vein, and the effect of treating myocardial infarction was evaluated after 14 days. The dose of NFT401 group was 5μg / mouse / day, and the PEG-PPS-PEG@NFT401 NPs group received 15μg / mouse / 3 days ( Figure 6 A).

[0107] Compared with PBS or PEG-PPS-PEG treatment, NFT401 or PEG-PPS-PEG@NFT401NPs treatment for 28 days significantly increased cardiac contractile function ( Figure 6 B). The infarct size of mice treated with NFT401 or PEG-PEG-PPS-PEG@NFT401 NPs was also significantly reduced ( Figure 6 C and D). There was no significant difference in cardiac function between the NFT401 group and the PEG-PPS-PEG@NFT401 NPs group ( Figure 6 Considering that NPs were injected at one-third the frequency compared with NFT401, these results suggest that PEG-PPS-PEG@NFT401 NPs can reduce the number of dosing times while exerting a similar therapeutic effect as naked NFT401.

[0108] We demonstrated that PEG-PPS-PEG@NFT401 NPs can effectively target the site of myocardial injury and deliver the NFT401 peptide. In addition, the material itself can reduce peroxide levels and prevent CM cell apoptosis. Compared with NFT401 alone, PEG-PPS-PEG@NFT401 NPs have a more effective therapeutic effect on myocardial infarction. Although its exact mechanism needs further study, this study proposes a new method for peptide drug targeting therapy of myocardial infarction and proposes a new approach for the treatment of heart disease.

[0109] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for preparing a damage-responsive nanopolymer, characterized in that: The steps include: (1) adding sodium hydroxide and toluenesulfonyl chloride solution to polyethylene glycol methyl ether solution in sequence for reaction, extracting the reaction solution, removing the solvent, and obtaining PEG-toluenesulfonyl; (2) dissolving PEG-toluenesulfonyl with a solvent to obtain a PEG-toluenesulfonyl solution; sequentially adding a potassium thioacetate solution and trimethylamine, incubating, filtering the precipitate and removing the solvent, extracting the remaining product, and removing the solvent to obtain polyethylene glycol thioacetate; (3) dissolving polyethylene glycol thioacetate with a solvent and degassing to obtain a polyethylene glycol thioacetate solution; sequentially adding sodium methoxide, propylene sulfide and iodoacetamide, reacting and precipitating to obtain a damage-responsive nano-copolymer PEG-PPS-PEG.

2. The method according to claim 1, characterized in that: In step (1), the ratio of sodium hydroxide, toluenesulfonyl chloride solution and polyethylene glycol methyl ether solution is 3-5 g:13-17 mL:15-25 mL; the concentration of the toluenesulfonyl chloride solution is 30-36 g / 100 mL; the concentration of the polyethylene glycol methyl ether solution is 7-8 g / 100 mL; the reaction time is 10-14 h; and the extraction is performed by using dichloromethane and water for 3 times.

3. The method according to claim 1, characterized in that The concentration of the PEG-toluenesulfonyl solution in step (2) is 4-5 g / 100 mL; the concentration of the potassium thioacetate solution is 11-12 g / 100 mL; the ratio of the PEG-toluenesulfonyl solution, the potassium thioacetate solution, and trimethylamine is 18-22 mL: 18-22 mL: 400-600 μL; and the extraction is performed by alternately extracting with dichloromethane and water for 3 times.

4. The method according to claim 1, characterized in that: The concentration of the polyethylene glycol thioacetate solution in step (3) is 3-5 g / 100 mL; the ratio of the polyethylene glycol thioacetate solution, sodium methoxide, propylene sulfide and iodoacetamide is 4-6 mL: 14-18 mg: 900-940 mg: 100-180 mg.

5. The method according to claim 1 or 4, characterized in that: In step (3), after adding sodium methoxide, the reaction time is 25 to 35 minutes, and then propylene sulfide is added; after adding propylene sulfide, the reaction time is 40 to 50 minutes, and then iodoacetamide is added; the reaction time is 10 to 14 hours.

6. The damage-responsive nano-copolymer PEG-PPS-PEG obtained by the preparation method according to any one of claims 1 to 5.

7. A drug delivery system, characterized in that It comprises the damage-responsive nano copolymer PEG-PPS-PEG as described in claim 6 and a hydrophilic polypeptide drug.

8. The drug delivery system according to claim 7, characterized in that The hydrophilic polypeptide drug is the GHRH agonist NFT401; the amino acid sequence of the GHRH agonist NFT401 is: PhAcTyr-dAla-Asp-Ala-Ile-Phe-Thr-Thr-Ser-Tyr-Arg-Orn-Val-Leu-Abu-Gln-Leu-Ser-Ala-Arg-Orn-Leu-Leu-Gln-Asp-Ile-Nle-Asp-Agm.

9. A pharmaceutical composition, characterized in that A drug delivery system comprising the drug delivery system of claim 7 or 8.

10. Use of the pharmaceutical composition according to claim 9 in preparing a drug for treating myocardial infarction.